Doctors have long known type 1 diabetes harms kidneys through body rust called oxidative stress. A new trial tests if alpha-lipoic acid, or ALA—a simple antioxidant pill—can fight back as extra help.
It is a three-month random study with 50 kidney-damaged type 1 patients split evenly: 25 took 300 mg ALA daily, 25 got standard care. The study was published in the Journal of Diabetes and its Complications. The researchers measured sugar control via HbA1c, kidney leak through urine albumin rate, harm marker malondialdehyde (MDA), and protection via total antioxidant capacity (TAC). They compared starts to 50 healthy type 1 patients and 50 without diabetes.
High Harm and Low Protection Mark Kidney Risk
Type 1 patients showed way more MDA and less TAC than healthy folks. Kidney patients topped that with even higher MDA and lower TAC. Harm marker MDA tied straight to high fats, albumin leaks, and poor sugar.
Pill Shifts Balance After Three Months
ALA group saw big drops in HbA1c, urine albumin, and MDA, plus TAC rise, all highly significant. Control group stayed flat.
Safe Add-On for Kidney Shield
ALA fights free radicals that scar kidney filters. This points to daily use for early protection.
Real Help for Diabetes Kidney Care
Endocrinologists and kidney doctors get a cost-effective tool to slow damage.
Featured
Off
Page Content
#ffffff
Anonymous user
On
Authenticated user
On
Premium
On
Paid / Sponsored
On
Key highlights
- Type 1 diabetes patients have higher MDA and lower TAC than controls, worse in those with diabetic nephropathy (P<0.01).
- MDA positively links to triglycerides (r=0.53), UAER (r=0.70), and HbA1c (r=0.5); TAC negatively links to them (r=-0.88 max).
- Three months of 300 mg/day ALA significantly cuts HbA1c, UAER, and MDA while raising TAC (P<0.01).
- ALA acts as adjuvant therapy without harming glycemic or renal function in T1D-DN.
- Findings support ALA to reduce oxidative stress and protect kidneys from diabetes harm.
Source
Elhenawy YI, Thabet RA, Hegazy et al. The role of oral alpha-lipoic acid as an adjuvant antioxidant therapy in diabetic nephropathy among children and adolescents with type 1 diabetes: a randomized controlled trial. J Diabetes Complications. 2026 Jan;40(1):109201. doi: https://doi.org/10.1016/j.jdiacomp.2025.109201
Thumbnail
Speciality
Currency
Sub Speciality
Sub Sub Speciality
Short Description
Three-month trial finds 300 mg daily alpha-lipoic acid lowers urine albumin, HbA1c, and oxidative damage markers in 25 type 1 diabetes patients with diabetic nephropathy.
User Segments
Release Date
Featured Order
0
Is Paid
0
Send Notification
Off